Covid-19 has given South Korea’s biotech firms a shot in the arm

UNTIL EARLY 2020 Seegene was a medium-sized South Korean purveyor of medical diagnostics with around $110m in annual sales. On January 27th that year Chun Jong-yoon, Seegene’s boss, and his counterparts at other biotechnology firms were summoned to an emergency meeting by the government. Officials asked if they could produce tests for a novel coronavirus which had been spreading rapidly in Wuhan, China. Seegene’s test kit was given the go-ahead by regulators. When cases began spiking soon afterwards in Daegu, in South Korea’s south-east, the company went into emergency mode. “We stopped all other activities and just threw everything we had at covid-19,” says Mr

→ Continue reading at The Economist

Similar Articles


Most Popular

Paramount+ adds The Women's Cup to its growing soccer lineup

Paramount+ is adding yet another major tournament to its streaming soccer coverage, and it's giving women's teams more time to shine. The ViacomCBS-owned service...

Razer reveals a more affordable version of its Opus headphones

Razer is releasing another version of its over-ear Opus headphones, with bright color options and a lower price. The Opus X offers active noise...

‘Disposable,’ ‘Ghost Bros,’ ‘Olivia and the Shadows’ to Pitch at Annecy’s La Liga Event

“Disposable,” “Ghost Bros” and “Olivia and the Shadows” feature among projects to be pitched from Monday June 14 at at an Ibero-American Animation Focus...